Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials

Journal of Clinical Oncology

Volumn 16, Issue 12, 1998, Pages 3832-3842

  Wheatley, Keith ^a  

^a CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PEPTICHEMIO; PREDNISONE; PROCARBAZINE; SEMUSTINE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0344076348     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.12.3832     Document Type: Article

References (40)

1. Gregory WM, Richards MA, Malpas JS: Combination chemotherapy versus melphalan and prednisone in the treatment of multiple myeloma: An overview of published trials. J Clin Oncol 10:334-342, 1992
2. Stewart LA, Parmar MKB: Meta-analysis of the literature or individual patient data: Is there a difference? Lancet 341:418-422, 1993
3. Clarke M, Gray R, Dunn J, et al: Combination chemotherapy for myelomatosis. Lancet 340:433, 1992
4. Stewart L, Clarke M: Practical methodology of meta-analyses (overviews) using updated individual patient data. Stat Med 14:2057-2079, 1995
5. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71-85, 1992
6. Hryniuk W, Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281-1288, 1984
7. Alexanian R, Bonnett J, Gehan E, et al: Combination chemotherapy for multiple myeloma. Cancer 30:382-389, 1972
8. McIntyre OR, Pajak T, Leone L, et al: Nitrosoureas in the treatment of multiple myeloma, in Nitrosoureas: Current Status and New Developments. 1981, pp 313-324
9. Harley JB, Pajak TF, McIntyre OR, et al: Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: A study of the CALGB. Blood 54:13-22, 1979
10. Abramson N, Lurie P, Mietlowski WL, et al: Phase III study of intermittent carmustine (BCNU), cyclophosphamide. and prednisone versus intermittent melphalan and prednisone in myeloma. Cancer Treat Rep 66:1273-1277, 1982
11. Cohen HJ, Silberman HR, Tornyos K, et al: Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma. Blood 63:639-648, 1984
12. Pavlovsky S, Corrado C, Santarelli MT et al: An update of two randomized trials in previously untreated multiple myeloma comparing melphalan and prednisone versus three-and five-drug combinations: A GATLA study. J Clin Oncol 6:769-775, 1988
13. Cavagnaro F, Lein JM, Pavlovsky S, et al: Comparison of two combination chemotherapy regimens for multiple myeloma: Methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone. Cancer Treat Rep 64:73-79, 1980
14. Bergsagel DE, Bailey AJ, Langley GR, et al: The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med 301:743-748, 1979
15. Brook J, Prasad R, Muthialu R: Sequential therapy compared with combination therapy in multiple myeloma. Arch Intern Med 135:163-171, 1975
16. Cooper MR, McIntyre OR, Propert KJ, et al: Single, sequential, and multiple alkylating agent therapy for multiple myeloma: ACALGB study. J Clin Oncol 4:1331-1339, 1986
17. Pavlovsky S, Saslavsky J, Tezanos Pinto M, et al: A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU, and vincristine in untreated multiple myeloma. J Clin Oncol 2:836-840, 1984
18. Salmon SE, Haut A, Bonnet JD, et al: Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: A Southwest Oncology Group study. J Clin Oncol 1:453-461, 1983
19. Durie BGM, Dixon DO, Carter S, et al: Improved survival duration with combination chemotherapy induction for multiple myeloma: A Southwest Oncology Group study. J Clin Oncol 4:1227-1237, 1986
20. Alexanian R, Dreicer R: Chemotherapy for multiple myeloma. Cancer 53:583-588, 1984
21. Tribalto M, Amadori S, Cantonetti M, et al: Treatment of multiple myeloma: A randomized study of three different regimens. Leuk Res 9:1043-1049, 1985
22. Riccardi A, Merlini G, Montecucco C, et al: Peptichemio. vincristine and prednisone versus melphalan and prednisone as induction therapy in multiple myeloma. Eur J Cancer Clin Oncol 22:787-791, 1986
23. Oken MM, Harrington DP, Abramson N, et al: Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma. Cancer 79:1561-1567, 1997
24. Hansen OP, Clausen NAT, Drivsholm A, et al: Phase III study of intermittent 5-drug regimen (VBCMP) versus intermittent 3-drug regimen (VMP) versus intermittent melphalan and prednisone (MP) in myelomatosis. Scand J Haematol 35:518-524, 1985
25. Medical Research Council Working Party on Leukaemia in Adults: Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Br J Cancer 52:153-158, 1985
26. Finnish Leukaemia Group: Treatment of multiple myeloma with an intensive 5-drug combination or intermittent melphalan and prednisone; A randomised multicentre trial. Eur J Haematol 48:37-40, 1992
27. Kildahl-Andersen O, Bjark P, Bondevik A, et al: Multiple myeloma in central Norway 1981-1982: A randomized clinical trial of 5-drug combination therapy versus standard therapy. Scand J Haematol 37:243-248, 1986
28. Kildahl-Andersen O, Bjark P, Bondevik A, et al: Multiple myeloma in central Norway 1981-1982: a follow-up study of a randomized clinical trial of 5-drug combination therapy versus standard therapy. Eur J Haematol 41:47-51, 1988
29. Osterborg A, Ahre A, Bjorkholm M, et al: Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/ prednisone in the treatment of multiple myeloma patients stage III - A randomized study from MGCS. Eur J Haematol 43:54-62, 1989
30. Peest D, Deicher H, Coldewey R, et al: Induction and maintenance therapy in multiple myeloma: a multicenter trial of MP versus VCMP. Eur J Cancer Clin Oncol 24:1061-1067, 1988
31. Peest D, Coldewey R, Deicher H: Overall vs. tumour-related survival in multiple myeloma. Eur J Cancer 27:672, 1991
32. Boccadoro M, Marmont F, Tribalto M, et al: Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high risk patients. J Clin Oncol 9:444-448, 1991
33. Hjorth M, Hellquist L, Holmberg E, et al: Initial treatment in multiple myeloma: No advantage of multidrug chemotherapy over melphalan-prednisone. Br J Haematol 74:185-191, 1990
34. Blade J, San Miguel JF, Alcala A, et al: Alternating combination VCMPA7BAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: A randomized multicentric study of 487 patients. J Clin Oncol 11:1165-1171, 1993
35. Riccardi A, Ucci G, Luoni R, et al: Treatment of multiple myeloma according to the extension of the disease: A prospective, randomised study comparing a less with a more aggressive cytostatic policy. Br J Cancer 70:1203-1210, 1994
36. Rossi JF, Bouabdallah R, Fuzibet JG, et al: Result of randomized study comparing melphalan-prednisone (MP) to alternative MP and hydroxyurea-VAD (vincristine, adriamycin. dexamethasone. HVAD) in 148 patients with multiple myeloma (MM). Blood 86:187a, 1995 (suppl 1, abstr)
37. Keldsen N, Bjerrum OW, Dahl IMS, et al: Multiple myeloma treated with mitoxantrone in combination with vincristine and prednisolone (NOP regimen) versus melphalan and prednisolone: A phase III study. Eur J Haematol 51:80-85, 1993
38. Peest D, Deicher H, Goldewey R, et al: A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group. Eur J Cancer 31A: 146-151, 1995
39. Shimizu K, Kamiya O, Hamajima N, et al: Multi-drug combination therapy with vincristine-melphalan-cyclophosphamide-prednisolone was more effective than cyclophosphamide-prednisolone in stage III myeloma. Jpn J Cancer Res 81:1320-1327, 1990
40. MacLennan ICM. Chapman C. Dunn J. et al: Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. Lancet 339:200-205, 1992